Many males age 50 and older must be tested yearly for best prostate health supplement cancer. Right now there are still 2 kinds of prostate cancer screening. The prostate-specific antigen (PSA) test as well as the electronic (finger) rectal exam.  
The first test measures the level of PSA in the bloodstream. PSA is a substance made largely by the prostate. Too much PSA of the blood may well indicate prostate cancer. However, high levels of PSA might additionally be indicative of illness, inflammation or maybe an enlarged prostate.  
The second test entails a physician or perhaps nurse putting a moisturized, gloved finger in to the rectum to check out the prostate for whatever and lumps else unusual.  
If both test raises a red-colored flag, physicians is possible to follow up with a prostate biopsy. This is currently the most correct way of checking out for cancer. While problems from the biopsy are fairly rare, they could lead to a urinary tract infection , as well as urinary and incontinence problems. In the United States, only an estimated 15 % of individuals that experience a biopsy actually are diagnosed with prostate cancer, while each biopsy costs over $1,000.  
Other non invasive assessments have been developed to alleviate discomfort.Improving identification and patient worry of patients with a high probability of prostate cancer would reduce the number of unnecessary biopsies.  
In November 2008, Italian investigators announced two proteins in the blood which gives the first warning yet of prostate cancer.  
The 4 researchers from Catania University and Milan's Tumour Institute say an unexplained surge in the proteins osteopontin as well as metalloprotease 9 is a' probable' sign of any prostate tumour developing. The Italian team says the brand new protein duo is able to catch it quicker compared to current testing methods.  
The head of the Biomedical Research Department at Catania Faculty, Franca Stivala, said the results were' promising' but required additional testing. The study was published in the journal Clinical Cancer Research.